The Extravascular Implantable Cardioverter Defibrillator System is a “first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins,” Medtronic said in an Aug. 28 news release.
Of the 316 participants in the study, which was published Aug. 28 in The New England Journal of Medicine, 92.6 percent did not experience any device complications at the six-month mark.
Medtronic did not release a timeline for when it might seek FDA approval but said it’s continuing its trials as “the agency reviews the company’s EV ICD pre-market application.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
